PhamaCan Announces Unexercised Expiry of Right of First Refusal on 48.5% Interest in Peace Naturals Project Investee

October 19, 2015

PhamaCan Announces Unexercised Expiry of Right of First Refusal on 48.5% Interest in Peace Naturals Project Investee

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES

TORONTO, ON–(Marketwired – October 15, 2015)

PharmaCan Capital Corp. (TSX VENTURE: MJN) (“PharmaCan” or the “Company”) announces the expiry unexercised of the previously disclosed right of first refusal to purchase a further 48.5% interest in investee The Peace Naturals Project (see press release October 9, 2015).

About PharmaCan Capital Corp.

PharmaCan is a company in the business of investing in companies either licensed, or actively seeking a license, to produce medical marihuana pursuant to Canada’s MMPR. PharmaCan has a diversified portfolio of investments including investments in 5 of the 26 companies licensed by Health Canada to produce medical marihuana.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT INFORMATION

720 King Street West, Suite 320

Toronto, Ontario M5V 2T3

Info@TheCronosGroup.com
Careers@TheCronosGroup.com

(416) 504-0004